Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas

Molecular Cancer Therapeutics

Volumn 14, Issue 4, 2015, Pages 857-864

  Dave, Nimita ^a,d   Chow, Lionel M L ^b   Gudelsky, Gary A ^a   LaSance, Kathleen ^a   Qi, Xiaoyang ^c   Desai, Pankaj B ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTROGEN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; LETROZOLE; TESTOSTERONE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYTOCHROME P450 1A1; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; BREAST TUMOR; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PENETRATION; FEMALE; GLIOMA; GLIOMA CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MTT ASSAY; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION; GENETICS; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRECLINICAL STUDY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GLIOMA; HUMANS; NITRILES; POSITRON-EMISSION TOMOGRAPHY; RATS; TRIAZOLES; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84982084151     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0743     Document Type: Article

References (19)

1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wollinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013;15 Suppl 2:1-56.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoom MJ, Janzer RC, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Silvera SA,Miler AB, Rohan TE. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer 2006;118:1321-4.
4. Kabat GC, Park Y, Hollenbeck AR, Schatzkin A, Rohan TE. Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP Diet and Health Study. Int J Cancer 2011;128: 944-50.
5. Kabat GC, Etgen AM, Rohan TE. Do steroid hormones play a role in the etiology of glioma? Cancer Epidemiol Biomarkers Prev 2010;19:2421-7.
6. Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol 2013;717:58-66.
7. Garcia-Segura LM. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol 2008;20:705-12.
8. Dave N, Gudelsky GA, Desai PB. The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. Cancer Chemother Pharmacol 2013;72: 349-57.
9. Cos S, Blask DE. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 2005;38:136-42.
10. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 1988;22:195-201.
11. Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011;19:305-16.
12. Apparaju SK, Gudelsky GA, Desai PB. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. Cancer Chemother Pharmacol 2008;61:223-9.
13. Fukuyama H, Hayashi T, Katsumi Y, Tsukada H, Shibasaki H. Issues in measuring glucose metabolism of rats brain using PET: the effect of Harderian glands on the frontal love. Neurosci Lett 1998;255:99-102.
14. Lonning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of thirdgeneration a aromatase inhibitors. SeminOncol 2003;30(4 Suppl 14):23-32.
15. Kohno M, Okamoto T, Suda K, Shimokawa M, Kitahara H, Shimamatsu S, et al. Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations. Clin Cancer Res 2014;20: 3613-22.
16. Shibahara Y, Miki Y, Onodera Y, Hata S, Chan MS, Yiu CC, et al. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol 2012;227:357-66.
17. Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, et al. Therapeutic significance of estrogen receptor b agonists in gliomas. Mol Cancer Ther 2012;11:1174-82.
18. Gandhari MK, Frazier CR, Hartenstein JS, Cloix JF, Bernier M, Wainer IW. Identification and characterization of estrogen receptor-related receptor alpha and gamma in human glioma and astrocytoma cells. Mol Cell Endocrinol 2010;315:314-8.
19. Balca-Silva J, Matias D, do Carmo A, Girao H, Moura-Neto V, Sarmento-Ribeiro AB, et al. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. Biochim Biophys Acta 2015;1850:722-32.